Newbridge Financial Services Group, Inc. Vertex Pharmaceuticals Inc Transaction History

Newbridge Financial Services Group, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Mar 28, 2024	SELL	$343.0 - $410.68 $20,237 - $24,230	-59 Reduced 71.08%	24 $9,000
Q3 2023 Oct 17, 2023	BUY	$338.18 - $362.46 $6,087 - $6,524	18 Added 27.69%	83 $28,000
Q1 2023 Apr 18, 2023	SELL	$283.23 - $323.1 $1,132 - $1,292	-4 Reduced 5.8%	65 $20,000
Q3 2022 Oct 13, 2022	SELL	$273.83 - $305.53 $2,464 - $2,749	-9 Reduced 11.54%	69 $20,000
Q2 2022 Jul 15, 2022	SELL	$234.96 - $292.55 $16,447 - $20,478	-70 Reduced 47.3%	78 $22,000
Q2 2021 Sep 07, 2021	SELL	$187.49 - $221.1 $6,749 - $7,959	-36 Reduced 19.57%	148 $30,000
Q1 2021 Sep 07, 2021	BUY	$207.02 - $241.31 $6,003 - $6,997	29 Added 18.71%	184 $40,000
Q4 2020 Sep 07, 2021	SELL	$207.01 - $276.09 $59,618 - $79,513	-288 Reduced 65.01%	155 $37,000
Q3 2020 Sep 07, 2021	BUY	$255.65 - $303.1 $113,252 - $134,273	443 New	443 $121,000

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Newbridge Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Newbridge Financial Services Group, Inc. with notifications on news.